Nurix Therapeutics, Inc. is a biopharmaceutical company focused on developing medicines that regulate the body’s natural protein-disposal systems to treat cancer and other serious diseases. The company’s approach centers on targeted protein modulation, including the use of small molecules to promote the degradation of disease-causing proteins or alter the activity of proteins involved in immune responses.
Nurix’s technology platform is built around E3 ligases, enzymes that help determine which proteins are marked for destruction inside cells. Using this platform, the company develops targeted protein degraders and molecular glues designed to eliminate or modify selected proteins that may contribute to cancer. Its pipeline has included oral investigational therapies targeting proteins involved in B-cell malignancies and immune-cell regulation, including BTK and Cbl-b.
The company’s research and development programs have included NX-5948, an orally administered BTK degrader being studied in B-cell cancers, and NX-1607, an investigational Cbl-b inhibitor intended to modulate immune-cell activity. Nurix has also pursued discovery and development collaborations with larger pharmaceutical companies, including Gilead Sciences, to apply its targeted protein degradation technology to additional therapeutic programs.
Nurix Therapeutics was founded in 2009 and is headquartered in San Francisco, California. Its operations are primarily focused on drug discovery and clinical development, with programs intended for patients in international oncology and immunology markets. The company’s common stock trades on the Nasdaq under the symbol NRIX.
AI Generated. May Contain Errors.
